Browsing by Subject "Breast Cancer"
Now showing items 1-8 of 8
-
(2020-10-27)Drug resistance is a fundamental barrier to developing robust antimicrobial and anticancer therapies. Its first sign was observed in the 1940s, soon after discovering penicillin, the first modern antibiotic. This dissertation ...
-
Investigating Singleminded 2s in Regulation of Breast Cancer Progression and Therapeutic Resistance (2022-08-17)Breast cancer is a leading cause of cancer-related death for women in the USA. Estrogen receptor positive breast cancers (ER+BC) comprise over 70% of BC cases and are targeted via ER modulation therapies. Despite this, ...
-
(Texas A&M University, 2005-08-29)Breast cancer has touched the lives of countless people, yet many women have misconceptions about the disease. One of the most common sources for breast cancer information used by American women is popular magazines. The ...
-
(Texas A&M University, 2007-04-25)The CAD gene is trifunctional and expresses carbamoylphosphate synthetase/aspartate carbamyltransferase/dihydroorotase, which are required for pyrimidine biosynthesis. CAD gene activities are induced in MCF-7 human breast ...
-
(2022-09-20)Dysregulation of cellular metabolism is a defining hallmark of breast cancer progression and is associated with metastasis and therapeutic resistance. The mechanisms by which cells undergo the switch from respiration to ...
-
(Texas A&M University, 2005-08-29)17β-Estradiol induces E2F-1 gene expression in ZR-75 and MCF-7 human breast cancer cells. Analysis of the E2F-1 gene promoter in MCF-7 cells previously showed that hormone-induced transactivation required interactions between ...
-
(2013-05-21)Ductal carcinoma in situ (DCIS) has been shown to be a precursor to invasive ductal cancer (IDC). Though the progression of DCIS to IDC is believed to be an important aspect of tumor aggressiveness, prognosis and molecular ...
-
(2012-05-03)Breast cancer affects a variety of individuals and currently encompasses a vast number of treatment plans. Two commonly used agents, Cyclophosphamide (C) and Adriamycin (A), will be used at clinical dosage on a progressive ...